World Journal of
Pharmaceutical and Life Sciences

TARGETED THERAPY IN SQUAMOUS CELL CARCINOMA: INVESTIGATING THE ROLE OF SYNTHETIC ANALOG MOLECULES

Syed Majid*, Sumaiyya Mehreen and Ayesha Munawar

ABSTRACT

Aim: To evaluate the cytotoxic effects of Benzaldehyde 3-chloro-4-fluorophenylhydrazone, a PD-1 immune checkpoint inhibitor, on kidney cancer cell lines and compare its efficacy with Cisplatin using various in vitro assays. Objective: To assess Benzaldehyde 3-chloro-4-fluorophenylhydrazone's potential as a therapeutic alternative or adjunct to Cisplatin for the treatment of Squamous Cell Carcinoma (SCC). Research: Kidney cancer cell lines were treated with different concentrations of Benzaldehyde 3-chloro-4-fluorophenylhydrazone and Cisplatin. Five cell viability assays were performed, namely MTT, CellTiter-Glo, Alamar Blue, Sulforhodamine B (SRB), and LDH cytotoxicity assays. The results showed a dose-dependent decrease in cell viability with Benzaldehyde 3-chloro-4-fluorophenylhydrazone, similar to the effects observed with Cisplatin. The LDH cytotoxicity assay indicated substantial cell membrane damage at higher Benzaldehyde 3-chloro-4-fluorophenylhydrazone concentrations, suggesting its potential as a cytotoxic agent. Conclusion: Benzaldehyde 3-chloro-4-fluorophenylhydrazone demonstrated strong cytotoxic effects across multiple assay methods and showed comparable efficacy to Cisplatin at higher concentrations. These findings suggest that Benzaldehyde 3-chloro-4-fluorophenylhydrazone could serve as a viable alternative or complement to traditional chemotherapy for SCC treatment, warranting further clinical investigations.

[Full Text Article]   [Download Certificate]